Dysregulated TGFb-ERK Signaling Drives Aberrant Extracellular Matrix Production in Noonan Syndrome-Associated Pulmonary Valve Stenosis
Clifford Z. LiuiD, Shrey D. PateliD, Simone SidoliiD, Aditi Prasad, Daniel CharytonowicziD, Amine MazineiD, Alexander A. MikryukoviD, Jamshid Abdul-GhafariD, Elizabeth S. Kahn, Dejauwne L. YoungiD, George Arthur Porter Jr.iD, Philip J. KatzmaniD, Stephen Pruett SandersiD, Chrystalle Katte CarreoniD, Dirk HubmacheriD, Joy LincolniD, Gordon M. KelleriD, Wendy K. ChungiD, Robert SebraiD, Bruce D. GelbiD
Abstract
Pulmonary valve stenosis (PVS) is the most common congenital heart defect in Noonan syndrome (NS) and related RASopathies, yet the molecular mechanisms linking pathogenic variants to the valve pathology remain poorly defined. Here, we utilized a human iPSC-based valve differentiation platform to generate the cardiac valve cell lineages--including fibrosa and spongiosa valve interstitial cell (VIC) subtypes. CRISPR-edited iPSCs harboring NS gain-of-function RAS/MAPK and Noonan syndrome with multiple lentigines (NSML) dominant-negative RAS/MAPK variants exhibited early defects in mesodermal and endocardial specification in all genotypes. Additionally, NS-iPSC endocardial cells exhibited defects in endothelial-to-mesenchymal transition (EndMT) specifically towards fibrosa VICs, which was most pronounced in PTPN11N308D (N308D) cells. Single-cell transcriptomics revealed widespread dysregulation of extracellular matrix (ECM) programs in N308D fibrosa VICs, including increased expression of collagens and proteoglycans, as well as dysregulation of multiple genes involved in ECM remodeling. We also detected activation of RAS-MAPK, TGF{beta}, and fibrosis-associated pathways in our transcriptional dataset. Mass spectrometry-based phosphoproteomics confirmed coordinated increases in ERK, PKC, and stress-related kinases, as well as enhanced activity of the TGF{beta} receptor. Functionally, N308D fibrosa VICs exhibited exaggerated upregulation of ECM genes in the presence of TGF{beta}2 ligand, suggesting that these cells are hypersensitive to TGF{beta} stimulation. Furthermore, we demonstrated that this pathological ECM-program occurs independently of BAMBI, a negative regulator of TGF{beta} signaling that was found to be decreased in N308D fibrosa VICs. Lastly, we performed histopathological analyses of stenotic pulmonary valves from two NS infants, which demonstrated marked overproduction and disorganization of ECM, mirroring the findings from our iPSC-based disease model. Together, our data reveal a central mechanism where NS-associated alleles sensitize fibrosa VICs to TGF{beta}, which leads to aberrant downstream signaling and drives the pathological ECM program in NS-associated PVS.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Alteration of myocardial structure and function in RAF1associated Noonan syndrome: Insights from cardiac disease modeling based on patient-derived iPSCs
S. Nakhaei-Rad, F. Bazgir, … M. R. Ahmadian·bioRxiv·Jan 22, 2022
- Insights into the Molecular Mechanism of Pulmonary Vein Stenosis in Pediatric Patients
Alyssa B. Kalustian, Pengfei Ji, … Ravi K. Birla·bioRxiv·Oct 9, 2024
- Cellular Interplay and Cytokine Hierarchy Cause Pathological Cardiac Hypertrophy in RAF1-Mutant Noonan Syndrome
J. C. Yin, M. J. Platt, … B. G. Neel·bioRxiv·Mar 30, 2017
- Rigosertib reverses hypertrophic cardiomyopathy in RAF1-associated Noonan syndrome
Levi Legler, Bing Xu, … Maria Irene Kontaridis·bioRxiv·Nov 25, 2024
- TSC2-extracellular matrix crosstalk controls pulmonary vascular proliferation and pulmonary hypertension
Yuanjun Shen, Dmitry A. Goncharov, … Elena A. Goncharova·bioRxiv·Aug 10, 2021
- ErbB Signalling is a Potential Therapeutic Target for Vascular Lesions with Fibrous Component
H. Ilmonen, S. Jauhiainen, … J. P. Laakkonen·bioRxiv·Sep 23, 2022